Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
Not all companies are created equal, and StockStory is here to surface the ones with real upside. That said, here are three cash-producing companies that don’t make the cut and some better opportunities instead.
Veralto (VLTO)
Trailing 12-Month Free Cash Flow Margin: 18.4%
Spun off from Danaher in 2023, Veralto (NYSE: VLTO) provides water analytics and treatment solutions.
Why Are We Wary of VLTO?
- Muted 4.1% annual revenue growth over the last four years shows its demand lagged behind its industrials peers
- Estimated sales growth of 6.3% for the next 12 months is soft and implies weaker demand
Veralto’s stock price of $87.09 implies a valuation ratio of 20.7x forward P/E. If you’re considering VLTO for your portfolio, see our FREE research report to learn more.
West Pharmaceutical Services (WST)
Trailing 12-Month Free Cash Flow Margin: 15.3%
Founded in 1923 and serving as a critical link in the pharmaceutical supply chain, West Pharmaceutical Services (NYSE: WST) manufactures specialized packaging, containment systems, and delivery devices for injectable drugs and healthcare products.
Why Does WST Give Us Pause?
- Sales trends were unexciting over the last two years as its 2.1% annual growth was below the typical healthcare company
- Efficiency has decreased over the last five years as its adjusted operating margin fell by 6.7 percentage points
- Eroding returns on capital suggest its historical profit centers are aging
West Pharmaceutical Services is trading at $246.88 per share, or 30.6x forward P/E. To fully understand why you should be careful with WST, check out our full research report (it’s free).
Avantor (AVTR)
Trailing 12-Month Free Cash Flow Margin: 7.6%
With roots dating back to 1904 and embedded in virtually every stage of scientific research and production, Avantor (NYSE: AVTR) provides mission-critical products, materials, and services to customers in biopharma, healthcare, education, and advanced technology industries.
Why Do We Avoid AVTR?
- Core business is underperforming as its organic revenue has disappointed over the past two years, suggesting it might need acquisitions to stimulate growth
- Estimated sales for the next 12 months are flat and imply a softer demand environment
- Earnings per share were flat over the last five years and fell short of the peer group average
At $7.69 per share, Avantor trades at 9.8x forward P/E. Dive into our free research report to see why there are better opportunities than AVTR.
Stocks We Like More
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren't just high-quality businesses. Something is happening with them right now. Elite fundamentals meeting near-term momentum — both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week's Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.
